Connexon Creative -

Prostate Cell News 1.22, June 18, 2010.

In this issue: Science News | Current Publications | Industry News | Policy News | Events

TOP STORY

Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
Castration-recurrent prostate cancer is suspected to depend on androgen receptor (AR). The AF-1 region in the amino-terminal domain (NTD) of AR contains most, if not all, of the transcriptional activity. Here researchers identify EPI-001, a small molecule that blocked transactivation of the NTD and was specific for inhibition of AR without attenuating transcriptional activities of related steroid receptors. [Cancer Cell]

Culture and Characterize Prostate Epithelial Progenitor Cells
with ProstaCult^™
by STEMCELL Technologies

CLICK HERE TO LEARN MORE

SCIENCE NEWS

New Prostate Cancer Research Will Have Global Impact
Combining radiation and hormone therapy in patients with high risk prostate cancer significantly improves the likelihood of patients living longer, according to a new NCIC Clinical Trials Group study conducted at Queen’s. [Queen's University Press Release]

University Hospitals Case Medical Center Cardiologists Discover Cancer Risks in Group of Blood Pressure Medications
Cardiologists have uncovered new research showing an increased risk of cancer with a group of blood pressure medications known as angiotensin-receptor blockers. [Press release from the University Hospitals Harrington-McLaughlin Heart & Vascular Institute discussing online prepublication in Lancet Oncology]

Polyphenols in Red Wine and Green Tea Halt Prostate Cancer Growth, Study Suggests
In what could lead to a major advance in the treatment of prostate cancer, scientists now know exactly why polyphenols in red wine and green tea inhibit cancer growth. [Press release from ScienceDaily discussing online prepublication in the FASEB Journal]

Compound Enhances Cancer-Killing Properties of Agent in Trials
Adding a second agent may make a new, experimental anti-cancer drug effective against a wide range of cancers, researchers have found. [Press release from the University of Illinois at Chicago College of Medicine discussing online prepublication in the Molecular Cancer Therapeutics]

Use ALDEFLUOR^® to Detect Prostate Precursor Cells
by STEMCELL Technologies

WATCH THE VIDEO

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Molecular Interplay of the Noncoding RNA ANRIL and Methylated Histone H3 Lysine 27 by Polycomb CBX7 in Transcriptional Silencing of INK4a
Here researchers report that chromobox 7 (CBX7) within the polycomb repressive complex 1 binds to ANRIL, and both CBX7 and ANRIL are found at elevated levels in prostate cancer tissues. [Mol Cell]

Shedding of RANKL by Tumor-Associated MT1-MMP Activates Src-Dependent Prostate Cancer Cell Migration
In this study, researchers show that membrane type 1 matrix metalloproteinase (MT1-MMP)-expressing LNCaP prostate cancer cells display enhanced migration. [Cancer Res]

Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells
Here, researchers surprisingly show that poly (ADP-ribose) polymerase 1 is hyperactivated in replicating BRCA2-defective cells. [Cancer Res]

Expression Profiling Identifies New Function of Collapsin Response Mediator Protein 4 as a Metastasis-Suppressor in Prostate Cancer
Researchers used a proteomics approach to screen for metastasis-associated proteins and found that collapsin response mediator protein-4 expression was inversely associated with the lymph node metastasis of prostate cancer. [Oncogene]

The Sphingosine Kinase-1 Survival Pathway is a Molecular Target for the Tumor-Suppressive Tea and Wine Polyphenols in Prostate Cancer
Here researchers provide the first evidence that dietary agents, namely, epigallocatechin gallate, resveratrol, or a mixture of polyphenols from green tea or grapevine extract, impede prostate cancer cell growth in vitro and in vivo by inhibiting the SphK1/S1P pathway. [FASEB J]

CD90/THY1 is Overexpressed in Prostate Cancer-Associated Fibroblasts and Could Serve as a Cancer Biomarker
Quantitative proteomic analysis of N-glycosylated proteins detected an increased amount of CD90/THY1 in cancer supernatants compared with non-cancer supernatants. [Mod Pathol]

Role of DNA Methyltransferase 1 in Hormone-Resistant Prostate Cancer
These findings provide evidence for therapeutically targeting DNA Methyltransferase 1 (DNMT1) in hormone-resistant prostate cancer. [J Mol Med]

Downregulation of the Nucleosome-Binding Protein 1 (NSBP1) Gene can Inhibit the In Vitro and In Vivo Proliferation of Prostate Cancer Cells
This study is to construct a lentiviral vector harboring an RNA interference sequence that targets the gene encoding the human high-mobility group nucleosomal binding protein 1; to study its role in inducing G2/M phase arrest and apoptosis in prostate cancer DU145 cells; and to assess the effect of its knockdown on cell proliferation in vitro and in vivo. [Asian J Androl]

Alpha1 and Beta1 Integrins Enhance the Homing and Differentiation of Cultured Prostate Cancer Stem Cells
The present study reports the integrin profile of prostate cancer progenitor cells and the role of alpha1 and beta1 integrins in the homing and differentiation of prostate cancer stem cells in vitro. [Asian J Androl]

CLINICAL RESEARCH

Results From a Phase I Clinical Study of the Novel Ii-Key/HER-2/neu(776-790) Hybrid Peptide Vaccine in Patients with Prostate Cancer
Researchers conducted the first Phase I trial of an Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine (AE37) with recombinant granulocyte macrophage colony-stimulating factor as adjuvant in patients with HER-2/neu+ prostate cancer. [Clin Cancer Res]

DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) Elicits Long-term T Cell Responses in Patients With Recurrent Prostate Cancer
Researchers have investigated plasmid DNA vaccines and have previously conducted a Phase I trial in which patients with recurrent prostate cancer were vaccinated with a DNA vaccine encoding prostatic acid phosphatase. [J Immunother]

INDUSTRY NEWS

Jevtana® (cabazitaxel) Injection Approved by U.S. FDA After Priority Review
Sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for Jevtana® (cabazitaxel) Injection in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer previously treated with a docetaxel-containing treatment regimen. [Sanofi-aventis Press Release]

OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
OncoMed Pharmaceuticals, Inc. and Bayer Schering Pharma AG, Germany, announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway. [OncoMed Pharmaceuticals, Inc. Press Release]

OncoVista Inc. Updates with Comprehensive Shareholder Letter
OncoVista Innovative Therapies, Inc. released a letter to shareholders from Chief Executive Officer, Alexander L. Weis Ph.D. to update shareholders on the Company's progress and potential. [The Wall Street Journal]

MMR Information Systems, Inc. Receives Grant From U.S. Patent and Trademark Office to Reinstate Patent to Treat Patients With B Cell Malignancies
MMR Information Systems, Inc. announced that a petition has been granted by the U.S. Patent and Trademark Office to reinstate its U.S. Patent titled "Method and Composition for Altering a B Cell Mediated Pathology". [Marketwire]

POLICY NEWS

The Path to Personalized Medicine
The leaders of the National Institutes of Health and the Food and Drug Administration have a shared vision of personalized medicine and the scientific and regulatory structure needed to support its growth. Together, they have been focusing on the best ways to develop new therapies and optimize prescribing by steering patients to the right drug at the right dose at the right time. [Food and Drug Administration and the National Institutes of Health, United States]

Diseased Cells Fail to Win Approval
In the latest obstacle to expanding the number of embryonic stem-cell lines eligible for U.S. federal funding, a National Institutes of Health committee has unanimously rejected dozens of cell lines carrying mutations for specific diseases. [National Institutes of Health, United States]

NIH Researchers Explore How Healthy, Young Adults View the Role Genetics Plays in Improving Health
Most healthy young adults place greater emphasis on health habits than on genetic risk factors when considering what causes common diseases, a research team from the National Human Genome Research Institute and the Henry Ford Health System in Detroit has found. [National Institutes of Health, United States]

Enhancing Peer Review: Advance Notice on Post-Submission Application Materials for NIH Training and Related Applications (NOT-OD-10-104) [National Institutes of Health, United States]

PFINDR: Phenotype Finder IN Data Resources: A Tool to Support Cross-Study Data Discovery Among NHLBI Genomic Studies (UH2/UH3) (RFA-HL-11-020) [National Institutes of Health, United States]

Clinical Trials for Medicines Section Updated [Medicines and Healthcare Products Regulatory Agency, United Kingdom]

Advertising and Supply of Therapeutic Goods to Complementary Healthcare Professionals: Schedule 1 to the Therapeutic Goods Regulations [Therapeutic Goods Administration, Australia]

EVENTS

21st Meeting of the European Association for Cancer Research (EACR)
June 26-29, 2010
Oslo, Norway

Translational Cancer Medicine 2010 - USA
July 11-14, 2010
San Francisco, United States

United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

2nd International Conference on Cellular and Molecular Bioengineering (ICCMB2)
August 2-4, 2010
Singapore City, Singapore

CHI's 5th Annual Immunotherapeutics and Vaccine Summit (ImVacS)
August 17-19, 2010
Cambridge, United States

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA)
August 23-27, 2010
Toronto, Canada

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences 2nd Annual World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

28th World Congress of Endourology and SWL
September 1-4, 2010
Chicago, United States

International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

35th European Society for Medical Oncology (ESMO) Congress
October 8–12, 2010
Milan, Italy

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

JOB OPPORTUNITIES

Senior Scientist - Magnetic Cell Separation (STEMCELL Technologies)

Business Development Manager Europe - Cell Therapy Products (Pall Corporation)

Sr. Product Support and Training Specialist (CardianBCT)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization's career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.

Learn more about Prostate Cell News: Archives | Events | Subscribe | Contact Us

Suite 201 - 375 West Fifth Avenue
Vancouver, BC V5Y 1J6, Canada